United Therapeutics’ Tyvaso (treprostinil) hit endpoints in a second phase 3 idiopathic pulmonary fibrosis (IPF) study, strengthening its case for a supplemental NDA review. The trial reportedly beat results from the first phase 3 study and positioned the company for a potential priority review, with a commercial launch target in 2027. Separately, Boston Scientific reported data from the Champion-AF trial for Watchman FLX, showing improved bleeding protection versus non-vitamin K oral anticoagulants while maintaining noninferiority for stroke, cardiovascular death, or systemic embolism. Together, the updates reflect continued momentum in both pharmacologic and procedural strategies for high-risk cardiopulmonary populations, with new evidence likely to influence future guideline discussions and sequencing in patient care.